284 related articles for article (PubMed ID: 16278416)
1. Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models.
Huizen IV; Wu G; Moussa M; Chin JL; Fenster A; Lacefield JC; Sakai H; Greenberg NM; Xuan JW
Clin Cancer Res; 2005 Nov; 11(21):7911-9. PubMed ID: 16278416
[TBL] [Abstract][Full Text] [Related]
2. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
3. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
[TBL] [Abstract][Full Text] [Related]
4. Mouse PSP94 expression is prostate tissue-specific as demonstrated by a comparison of multiple antibodies against recombinant proteins.
Thota A; Karajgikar M; Duan W; Gabril MY; Chan FL; Wong YC; Sakai H; Chin JL; Moussa M; Xuan JW
J Cell Biochem; 2003 Apr; 88(5):999-1011. PubMed ID: 12616537
[TBL] [Abstract][Full Text] [Related]
5. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
[TBL] [Abstract][Full Text] [Related]
6. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Duan W; Gabril MY; Moussa M; Chan FL; Sakai H; Fong G; Xuan JW
Oncogene; 2005 Feb; 24(9):1510-24. PubMed ID: 15674347
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.
Reeves JR; Dulude H; Panchal C; Daigneault L; Ramnani DM
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6018-22. PubMed ID: 17062675
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
9. Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I). Immuno-dominant and immuno-recessive area.
Xuan JW; Wu D; Guo Y; Garde S; Baijal-Gupta M; Chin JL
J Cell Biochem; 1997 May; 65(2):172-85. PubMed ID: 9136076
[TBL] [Abstract][Full Text] [Related]
10. Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (II). Epitope mapping by monoclonal antibodies.
Xuan JW; Wu D; Guo Y; Huang CL; Wright GL; Chin JL
J Cell Biochem; 1997 May; 65(2):186-97. PubMed ID: 9136077
[TBL] [Abstract][Full Text] [Related]
11. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
Gabril MY; Duan W; Wu G; Moussa M; Izawa JI; Panchal CJ; Sakai H; Xuan JW
Mol Ther; 2005 Mar; 11(3):348-62. PubMed ID: 15727931
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice.
Lyons SK; Lim E; Clermont AO; Dusich J; Zhu L; Campbell KD; Coffee RJ; Grass DS; Hunter J; Purchio T; Jenkins D
Cancer Res; 2006 May; 66(9):4701-7. PubMed ID: 16651422
[TBL] [Abstract][Full Text] [Related]
13. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154
[TBL] [Abstract][Full Text] [Related]
14. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
Meyer-Siegler KL; Iczkowski KA; Vera PL
BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of PSP94 in rat prostate lobes as demonstrated by an antibody against recombinant GST-PSP94.
Kwong J; Chan FL; Jiang S; Guo Y; Imasato Y; Sakai H; Koropatnick J; Chin JL; Xuan JW
J Cell Biochem; 1999 Sep; 74(3):406-17. PubMed ID: 10412042
[TBL] [Abstract][Full Text] [Related]
16. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
Gross M; Top I; Laux I; Katz J; Curran J; Tindell C; Agus D
Clin Cancer Res; 2007 Apr; 13(7):1979-86. PubMed ID: 17404077
[TBL] [Abstract][Full Text] [Related]
17. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
[TBL] [Abstract][Full Text] [Related]
18. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
Kasper S
J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
[TBL] [Abstract][Full Text] [Related]
19. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.
Gabril M; Xuan J; Moussa M; Dinney CP; Chin JL; Izawa JI
Urology; 2004 Dec; 64(6):1233-7. PubMed ID: 15596214
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
